LONDON, May 12, 2026
Isomorphic Labs has secured a massive $2.1 billion Series B funding round to accelerate the expansion of its artificial intelligence-powered drug discovery platform, marking one of the largest financing rounds in the rapidly growing AI-driven biopharmaceutical sector. The company announced that the funding will be used to scale its proprietary AI drug design engine, expand therapeutic programs toward clinical development, and strengthen its global research and engineering infrastructure.
The financing round was led by Thrive Capital and included participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ international investor base and reinforcing confidence in the company’s AI-first approach to pharmaceutical innovation.
Founded in 2021 and led by Sir Demis Hassabis, Isomorphic Labs has quickly emerged as one of the most closely watched biotechnology companies operating at the intersection of artificial intelligence, computational biology, and drug development. The company is focused on transforming traditional pharmaceutical research by applying advanced AI models capable of accelerating target identification, molecular design, and therapeutic optimization.
AI Drug Design Platform Gains Global Momentum
According to the company, the newly raised capital will primarily support the continued development of its proprietary IsoDDE AI drug design engine, which integrates multiple AI models capable of working across various therapeutic areas and drug modalities. Isomorphic Labs stated that the platform is designed to improve predictive accuracy while significantly reducing the time required to identify viable drug candidates.
Advertisement
Executives at the company described the financing as a major validation of Isomorphic Labs’ scientific and technological progress. Founder and CEO Sir Demis Hassabis stated that the investment demonstrates growing confidence in the company’s ability to scale AI-driven drug discovery and ultimately transform medicine development globally.
Company President Max Jaderberg emphasized that the AI drug design engine has already demonstrated strong performance across internal therapeutic programs by rapidly identifying viable drug candidates. He noted that the platform provides a repeatable framework for designing new medicines across a broad range of diseases with unprecedented speed and precision.
Strategic Partnerships Strengthen Biopharma Position
Isomorphic Labs has also strengthened its position in the pharmaceutical industry through collaborations with major global drugmakers including Novartis, Eli Lilly, and Johnson & Johnson. The company said these strategic partnerships validate the commercial and scientific value of its AI-powered drug discovery approach while supporting the development of next-generation therapeutics.
The company explained that its AI platform bridges the gap between protein structure prediction and real-world drug discovery applications. By integrating proprietary foundational AI models with large-scale biological data, the platform aims to enable researchers to better understand disease mechanisms and optimize therapeutic candidates with greater efficiency than traditional discovery methods.
Industry experts continue to view AI-driven drug discovery as one of the most transformative areas in biotechnology, with pharmaceutical companies increasingly investing in machine learning and predictive biology to accelerate clinical pipelines and reduce development costs. Isomorphic Labs’ latest funding round reflects growing investor confidence that artificial intelligence may significantly reshape the future of pharmaceutical research and development.
Expanding Global AI and Clinical Capabilities
The company confirmed that part of the funding will support aggressive global hiring efforts focused on attracting top talent in AI engineering, drug design, biology, and clinical development. Isomorphic Labs currently operates from London while maintaining additional offices in Cambridge, Massachusetts and Lausanne, Switzerland.
As competition intensifies in the AI-biotech sector, Isomorphic Labs is positioning itself as a leader in next-generation drug discovery by combining advanced computational capabilities with pharmaceutical development expertise. The latest investment is expected to accelerate the company’s transition from AI model development to clinical-stage therapeutic innovation, potentially redefining how new medicines are discovered and developed worldwide.
Source: Isomorphic Labs press release
